Definitive Healthcare (DH) 27th Annual Needham Growth Conference summary
Event summary combining transcript, slides, and related documents.
27th Annual Needham Growth Conference summary
3 Feb, 2026Business overview and strategy
Focuses on mapping the U.S. healthcare system with proprietary data and analytics, serving customers aiming to sell or compete in healthcare.
Expanded from core reference data to include third-party insights and analytics, targeting a $10 billion TAM.
Recent leadership changes brought a focus on product and go-to-market reinvigoration, emphasizing modern data delivery and distribution partnerships.
Unified platform development is underway to integrate acquired products, aiming for a common UI/UX and streamlined access.
Simplification and acceleration of master data management and digital activation initiatives are prioritized.
Market dynamics and competitive landscape
Faces competition from large platform players bundling data and point solution providers competing on price.
Value-based selling and deep healthcare domain expertise are key differentiators, with interoperability across platforms.
Sales cycles have lengthened due to more complex buying processes and increased involvement from risk, compliance, and finance departments.
M&A in the industry can both create opportunities and lead to vendor rationalization, depending on the acquiring organization’s philosophy.
Sales, go-to-market, and operational changes
Sales force restructured for directness and simplicity, reducing handoffs and aligning compensation with customer success.
New compensation and onboarding processes were collaboratively developed and launched, aiming for better continuity and customer engagement.
KPIs and dashboards are being aligned with operational management, focusing on lead creation, pipeline tracking, and predictive analytics.
Resource allocation is increasingly data-driven, with vertical-specific ROI analysis guiding spend and focus.
Latest events from Definitive Healthcare
- Q2 2026 revenue fell 9% but profit exceeded guidance amid innovation and ongoing macro headwinds.DH
Q2 2026 - Q1 2026 met guidance with improved margins despite a $197.2M goodwill impairment charge.DH
Q1 2026 - Director elections, auditor ratification, equity plan increase, and say-on-pay up for vote.DH
Proxy filing - Annual meeting covers director elections, auditor ratification, equity plan amendment, and say-on-pay.DH
Proxy filing - Q4 and full year 2025 beat guidance, but goodwill impairments led to large net losses.DH
Q4 2025 - Turnaround strategy drives stability, renewal gains, and innovation amid sector headwinds.DH
Morgan Stanley 23rd Annual Global Healthcare Conference - Q2 revenue and adjusted EBITDA rose, but a $363.6M goodwill impairment drove a large net loss.DH
Q2 2024 - Q3 revenue beat guidance, but net loss deepened on goodwill impairment; $100M buyback announced.DH
Q3 2024 - Q1 2025 revenue beat guidance, but a $176.5M goodwill impairment drove a net loss.DH
Q1 2025